drugset / Trial / NCT01936064

The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients

NCT01936064

Phase 1/2 Unknown 60 enrolled Lagos State University
RandomizedParallel-groupTriple-blindTreatment

Summary

To determine the effective functionality/potency of Jobelyn as an immunologic and haematologic booster in Breast cancer patients (start-off), thus improving the outlook and the quality of life of such patients generally

Timeline

Start
2016-10
Primary completion
2017-10
Completion
2018-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclophosphamide Other / unclassified
Comparator Epirubicin Small molecule

Indications